Ranibizumab

雷珠单抗

Report date: 2026/05/09 20:00:18

Base Information

Drug NameRanibizumab
Drug Alias Name雷尼比珠单抗VEGF antibody fragmentAnti-VEGF fragmentrhuFab V2 AMDRanibizumabum +[17] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaMacular telangiectasiaPolypoidal choroidal vasculopathy +[56] 
Global Approved IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration +[4] 
Approved Indications in ChinaMacular Degeneration
Original Approved Country/TerritoryUnited States
Original Approved Date2006/06/30
Country/TerritoryCzechiaBelgiumCanada +[57] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma AgGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesGenerium PharmaceuticalsIncepta Pharmaceuticals LtdUniversity Of Giessen +[12] 
Inactive CompaniesUtah State UniversitySouth Coast Retina Center; Carson, Mcbeath, Boswell IncUniversity Of California San Francisco +[44] 
Active IndicationsDiabetic macular oedemaUveitisChoroidal Neovascularization +[13] 
Inactive IndicationsMacular telangiectasiaPolypoidal choroidal vasculopathyMacular telangiectasia 2 +[43] 

Other Information

ATC CodeS01LA04
Related LinksWikipediaDrugBankKEGG